title: Effector cells working for rejection of Ad12 tumors in mice.
abstract: Immune spleen cells (ISC) capable of inhibiting the growth of adenovirus type 12 (Ad12) tumors were raised in C57BL/6 mice by immunization with Ad12, fractionated according to their affinity for plastic and nylon-wool substrates or treated with various antisera plus complement, and subjected to the tumor-neutralization test (Winn) to define the effector cells for the cell species. Full antitumor activity of ISC was recovered in the cell fractions nonadherent to the two substrates; the antitumor activity of ISC was abrogated entirely by anti-Thy-1,2 serum and almost entirely by anti-Lyt-2.2 ascites fluid plus complement. These results clearly indicate that T-lymphocytes, particularly those bearing Lyt-2.2 antigen, are the principal effectors in ISC against Ad12 tumors in animals.
mesh_terms: D000257:Adenoviridae Infections / Q000276:immunology*; D000258:Adenovirus Infections, Human / Q000276:immunology*; D000818:Animals; D000961:Antilymphocyte Serum / Q000494:pharmacology; D001202:Ascitic Fluid / Q000276:immunology; D002448:Cell Adhesion; D002472:Cell Transformation, Viral; D003165:Complement System Proteins / Q000502:physiology; D003602:Cytotoxicity, Immunologic; D006801:Humans; D007518:Isoantibodies / Q000502:physiology; D051379:Mice; D008810:Mice, Inbred C57BL; D009374:Neoplasms, Experimental / Q000276:immunology; D013154:Spleen / Q000166:cytology / Q000276:immunology*; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology
chemical_list: D000961:Antilymphocyte Serum; D007518:Isoantibodies; C029805:Lyt antibodies; D003165:Complement System Proteins